MedTrace Logo

Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis

NCT03089775 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2017-07-17

No results posted yet for this study

Summary

This two cohort study (Cohort A and B) is being conducted to assess the safety and efficacy of BBI-2000 for the prevention (Cohort A) and treatment (Cohort B) of delayed type hypersensitivity reaction.

Conditions

  • Contact Dermatitis

Interventions

DRUG

BBI-2000

Experimental

DRUG

Vehicle

Vehicle Comparator

OTHER

Multiple treatments

BBI-2000, Vehicle, Clobetasol Propionate, No treatment

Sponsors & Collaborators

  • Fresh Tracks Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Lawrence A Romel, MS · Fresh Tracks Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-14
Primary Completion
2017-05-24
Completion
2017-05-24

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03089775 on ClinicalTrials.gov